Type 2 Diabetes, Liver Cirrhosis
Conditions
Keywords
Diabetes, Cirrhosis, Insulin, Inpatient
Brief summary
Liver disease is an important cause of death in type 2 diabetes. In the population-based Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths. In another prospective cohort study , cirrhosis accounted for 12.5% of deaths in patients with diabetes. In Egypt hepatitis C virus the commonest of cirrhosis here has a prevalence of 9.8% in the population with the greatest burden over national health care bills. Patients with cirrhosis & type 2 diabetes mellitus are always showing up in all hospital wards without a clear consensus of best management of their hyperglycemia.
Detailed description
Best management of hyperglycemia in non-intensive care unit Cirrhotic patients with type 2 diabetes by different insulin regimens either sliding scale regular insulin or basal bolus insulin using NPH & regular insulin or Glargine & Glulisine.
Interventions
DRUGGlargine & Glulisine
Basal Glargine & bolus Glulisine
DRUGRegular insulin
Sliding scale regular insulin
DRUGNPH & regular insulin
Basal NPH & bolus regular insulin
Sponsors
Sanofi
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Hospitalized type 2 Diabetes Mellitus with liver cirrhosis * Entry blood glucose (fasting or random) greater than 180 mg%
Exclusion criteria
* Type 1 Diabetes Mellitus * Pregnancy * Steroids: prednisone greater than 7.5mg/day or equivalent * Serum Creatinine \> 3 mg/dl * Patients in intensive care units.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| optimal glycemic control in inpatient cirrhotics | 3-7 days |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of hypoglycemic episodes | 3-7 days |
Countries
Egypt
Contacts
Primary ContactMostafa M Alfishawy, MB BCh
Outcome results
None listed